Executive Chairman of Board
Vincent LoPriore has served as a member of our board of directors since April 2025. Mr. LoPriore is an experienced financial professional with over 30 years of experience in the investment banking industry. He began his career at Oppenheimer & Co. in 1989 and subsequently held senior positions at Legg Mason, Inc. and partner at C.E. Unterberg, Towbin, where he led the special equities group and completed more than $150 million in private placement transactions. He has served in leadership roles at various boutique and mid-sized investment firms, focusing on capital raising, regulatory navigation. Mr. LoPriore is currently a Partner and licensed representative at President Street Global, LLC, a FINRA-registered broker-dealer. He also serves as the investment manager of the Gravitas Capital LP Fund, with a track record of strong investment performance. Mr. LoPriore has longstanding relationships within the biomedical industry and supports philanthropic initiatives including Race to Erase MS and Cure Addiction Now. Mr. LoPriore’s extensive investment banking experience and sector expertise support his qualifications to serve on the Board of Directors.
Independent Director
Gary Stetz has served as a member of our board of directors since April 2025. Mr. Stetz is a Certified Public Accountant with over 35 years of experience across accounting, finance, business valuation and corporate governance. Mr. Stetz currently serves as Managing Partner of Stetz, Belgiovine, Manwarren and Wallis P.C., an accounting, auditing, tax compliance and advisory services firm with more than 1,000 corporate clients. His extensive leadership experience includes founding Allegiance Community Bank and serving on the Board of BCB Bancorp. He is co-author of the book Project Management Accounting. He has earned multiple professional credentials, including Certified Mediator, Certified Fraud Examiner, and Chartered Global Management Accountant Mr. Stetz’s extensive expertise in financial forensics, valuation, and regulatory compliance will provide valuable oversight as Tharimmune continues to build a strong financial and operational foundation. Mr. Stetz’s extensive financial, accounting, and governance experience supports his qualifications to serve on the Board of Directors.
Independent Director
Clay Kahler has served as a member of our board of directors since April 2025. Mr. Kahler is a seasoned entrepreneur with decades of leadership experience in life sciences, biotechnology, and technology ventures. He is the Co-founder, CEO, and Managing Director of Spray Labs, LLC, an FDA-registered, cGMP-certified manufacturer specializing in oral spray drug delivery technologies. He is also the Founder and CEO of Gateway Sciences LLC, a company focused on regenerative medicine and mental health. Mr. Kahler co-founded Helius Medical Technologies, Inc. (NASDAQ: HSDT), where he played a pivotal role in structuring early corporate financing, facilitating the company’s public listing, and establishing strategic partnerships including worked with the team to secure a multi-million dollar Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Defense, through the U.S. Army Medical Research and Materiel Command (USAMRMC). These efforts helped propel the company to a peak market capitalization of approximately $500 million. He has also held multiple corporate advisory positions including UK-based Velocity Mobile Limited, doing business as Velocity Black, which was successfully acquired by Capital One Financial Corporation (NYSE: COF) in June 2023 for approximately $300 million. Mr. Kahler’s extensive leadership experience in public company operations, capital markets, and life sciences supports his qualifications to serve on the Board of Directors.
Independent Director
Sanam Parikh has served as a member of our board of directors since November 2024. Mr. Parikh has more than five years of experience in clinical research, project management, and laboratory operations. He currently serves as a Clinical Trial Manager at Schrödinger, where he has been employed since March 2022. Previously, he served as an Assistant Project Manager at Clario and as a Lab Technologist at Q Answer Lab. Mr. Parikh holds a Bachelor’s degree in Biology from the New Jersey Institute of Technology and a Master of Public Health from Rutgers University. Mr. Parikh’s experience in clinical trial management and life sciences supports his qualifications to serve on the Board of Directors.
Independent Director
James Gordon Liddy (CDR US Navy SEAL (Ret)) has served on our Board since June 2025 and is an internationally recognized expert on counterterrorism and critical infrastructure protection. Mr. Liddy brings a distinguished career and unparalleled expertise in national security and preparedness. As the Senior Advisor to the Director for Strategy, Policy and Initiatives for the Office of the Assistant Secretary of Defense for Special Operations and Low Intensity Conflict, and previously the Chief of Plans and Policy for the United States Special Operations Command’s Washington Office, he played a pivotal role in designing and coordinating policy, operational plans, and strategic initiatives for the Global War on Terrorism. His experience as a member of a highly classified national security program further underscores his deep understanding of the threats facing the nation. Notably, CDR Liddy’s tenure as the Combating Terrorism and Special Operations Officer for the Chief of Naval Operations saw him as the principal architect for the Navy’s Anti-Terrorism Force Protection Plan and the leader of the Navy’s elite Antiterrorism Assessment Team (Red Cell). He also spearheaded the creation of DoD’s Anti-terrorism and Force Protection Plan DoD Directive 20012.H, demonstrating his capability to develop and implement critical protective measures at the highest levels of government. Mr. Liddy’s extensive experience and service support his qualifications to serve on the Board of Directors.
